Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444256 · ClinicalTrials.gov registry record · Phase 2
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
A Phase 2 study of Stimulant Use Disorder, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06444256: Recruiting Phase 2 study of Stimulant Use Disorder, sponsored by The University of Texas Health Science Center, Houston.
NCT06444256 is a Phase 2 study of Stimulant Use Disorder that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants, below the 208-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06444256, a Phase 2 study of Stimulant Use Disorder, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.
Conditions Studied
Interventions
- DRUG SUVO
- DRUG TAU
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
What NCT06444256 shows while recruiting
NCT06444256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 208-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Stimulant Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which SUVO is the first listed.
NCT06444256 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06444256 about?
NCT06444256 is a clinical study titled "Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder". The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS)...
What is the current status of trial NCT06444256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-07-25. Estimated completion is 2027-01-30.
What conditions does trial NCT06444256 study?
This clinical trial studies the following conditions: Stimulant Use Disorder.
What interventions are being tested in trial NCT06444256?
The interventions under investigation include: SUVO (DRUG), TAU (DRUG).
Who is sponsoring clinical trial NCT06444256?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06444256 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stimulant Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06444256's enrollment target sits among peer trials
20 9th of 9 higher than 1 of 9 other Stimulant Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stimulant Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
RECRUITING · Phase 2
-
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
RECRUITING · NA
-
Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use
RECRUITING · NA
-
Smartphone Services for Stimulant Use Disorder
RECRUITING · NA
-
Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder
RECRUITING · Phase 1
-
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI